<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000600472"><TermName>Angiocept</TermName><TermPronunciation>(AN-jee-oh-sept)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. Angiocept may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent. Also called CT-322 and VEGFR-2 inhibitor CT-322.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720635" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Angiocept&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720634" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Angiocept&quot;" language="es" id="_4"/><SpanishTermName>Angiocept</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Angiocept podría prevenir la formación de vasos sanguíneos nuevos que los tumores necesitan para crecer y podría destruir células cancerosas. Es un tipo de inhibidor del receptor del factor de crecimiento endotelial vascular-2 (RFCEV-2) y un tipo de antiangiogénico. También se llama CT-322 y inhibidor del RFCEV-2 CT-322.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-07-14</DateFirstPublished><DateLastModified>2009-04-21</DateLastModified></GlossaryTerm>
